среда, 31 августа 2016 г.

Novartis wins Us Ok for biosimilar version of Amgen's Enbrel

Novartis wins Us Ok for biosimilar version of Amgen's Enbrel


U.S. regulators on Tuesday approved the first lower-cost version of Enbrel, a blockbuster anti-inflammatory drug from Amgen that is among the top-selling drugs in the world. The Food and Drug Administration cleared the near-copy of the drug, dubbed Erelzi, developed by Swiss drug giant Novartis, which would not disclose the planned list price for the drug.



from Biotech News